MA50675B1 - Inhibiteurs de la creb binding protein (cbp) - Google Patents
Inhibiteurs de la creb binding protein (cbp)Info
- Publication number
- MA50675B1 MA50675B1 MA50675A MA50675A MA50675B1 MA 50675 B1 MA50675 B1 MA 50675B1 MA 50675 A MA50675 A MA 50675A MA 50675 A MA50675 A MA 50675A MA 50675 B1 MA50675 B1 MA 50675B1
- Authority
- MA
- Morocco
- Prior art keywords
- cbp
- bromodomains
- family
- inhibitors
- binding protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des inhibiteurs de la famille cbp/p300 de bromodomaines. Les composés peuvent être utiles dans le traitement d'une maladie ou de troubles associés à l'inhibition de la famille cbp/p300 de bromodomaines. Par exemple, l'invention concerne des composés et des compositions pour l'inhibition de la famille cbp/p300 de bromodomaines, des procédés de traitement, de prévention ou d'amélioration de maladies ou de troubles associés à l'inhibition de la famille cbp/p300 de bromodomaines, et des procédés de synthèse de ces composés. <img file="imga0001.Tif" frnum="0001" he="63" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="85"/>
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (fr) | 2017-09-15 | 2018-09-14 | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| PCT/US2018/051235 WO2019055877A1 (fr) | 2017-09-15 | 2018-09-14 | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| PCT/US2019/039936 WO2020006483A1 (fr) | 2018-06-29 | 2019-06-28 | Inhibition de la protéine de liaison à creb (cbp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50675A MA50675A (fr) | 2021-04-07 |
| MA50675B1 true MA50675B1 (fr) | 2021-09-30 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50675A MA50675B1 (fr) | 2018-06-29 | 2019-07-01 | Inhibiteurs de la creb binding protein (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (fr) |
| EP (1) | EP3998266A1 (fr) |
| JP (4) | JP6781806B2 (fr) |
| KR (2) | KR20250067962A (fr) |
| CN (2) | CN112513038B (fr) |
| AU (3) | AU2019295790B2 (fr) |
| BR (1) | BR112020026783A2 (fr) |
| CA (1) | CA3105099A1 (fr) |
| CY (1) | CY1124762T1 (fr) |
| DK (1) | DK3587418T3 (fr) |
| ES (1) | ES2900105T3 (fr) |
| HR (1) | HRP20211698T1 (fr) |
| HU (1) | HUE056885T2 (fr) |
| IL (3) | IL313466B2 (fr) |
| LT (1) | LT3587418T (fr) |
| MA (1) | MA50675B1 (fr) |
| MX (2) | MX2023013508A (fr) |
| PL (1) | PL3587418T3 (fr) |
| PT (1) | PT3587418T (fr) |
| RS (1) | RS62732B1 (fr) |
| SA (1) | SA520420909B1 (fr) |
| SG (1) | SG11202012767UA (fr) |
| SI (1) | SI3587418T1 (fr) |
| SM (1) | SMT202100636T1 (fr) |
| WO (1) | WO2020006483A1 (fr) |
| ZA (2) | ZA202100509B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250067962A (ko) * | 2018-06-29 | 2025-05-15 | 포르마 세라퓨틱스 인크. | Creb 결합 단백질(cbp)의 저해 |
| BR112021018266A2 (pt) * | 2019-03-15 | 2022-02-01 | Forma Therapeutics Inc | Composições e métodos para tratar formas positivas de receptor andrógeno de câncer |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| BR112022025911A2 (pt) | 2020-06-25 | 2023-01-10 | Tolremo Therapeutics Ag | Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante |
| AU2021298154A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| DE60134886D1 (de) | 2000-11-20 | 2008-08-28 | Merck Patent Gmbh | Chirale photoisomerisierbare verbindungen |
| WO2003033517A1 (fr) | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Modulateurs de ship 1 |
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (fr) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (fr) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Inhibiteurs tetracycliques de janus kinases |
| WO2007120339A1 (fr) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Inhibiteurs de pyrimidine kinase |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| AU2007249827A1 (en) | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| EP1878724A1 (fr) | 2006-07-15 | 2008-01-16 | sanofi-aventis | Synthèse régiosélective des benzimidazoles et azabenzimidazoles catalysée par le palladium |
| CA2574531C (fr) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Promoteurs de l'acetylation d'hat et utilisations de compositions contenant ceux-ci pour promouvoir l'immunogenicite |
| WO2008157680A2 (fr) | 2007-06-21 | 2008-12-24 | The Wistar Institute | Procédés et compositions servant à moduler l'activité de la p300/cbp |
| AU2008267444A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | １１β−ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| DK2303021T3 (en) | 2008-06-16 | 2019-04-08 | Univ Tennessee Res Found | RELATIONSHIPS FOR TREATING CANCER |
| WO2010110380A1 (fr) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | Composé de pipéridine condensé et agent pharmaceutique le contenant |
| US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| CA2758904C (fr) | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Nouveaux composes du type mimetique a spire inversee, procede pour leur preparation et utilisation |
| CA2763008A1 (fr) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines comme inhibiteurs de pi3k/mtor, methodes d'utilisation e t de fabrication benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture |
| WO2010138490A1 (fr) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazèpines comme inhibiteurs de mtor et méthodes d'utilisation et de fabrication |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| KR101939704B1 (ko) | 2010-03-01 | 2019-01-17 | 지티엑스, 인코포레이티드 | 암 치료용 화합물 |
| CA2800618C (fr) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Composes heteroaryles et leurs procedes d'utilisation |
| WO2012019093A1 (fr) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Composés synthétiques et procédés pour diminuer l'auto-administration de nicotine |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| WO2012116135A2 (fr) | 2011-02-24 | 2012-08-30 | Emory University | Compositions antagonistes de noggine pour ossification et procédés associés à celles-ci |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (fr) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | Inhibiteurs de p300/cbp et leurs méthodes d'utilisation |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| IN2015DN02008A (fr) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| WO2015004533A2 (fr) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines |
| WO2015013635A2 (fr) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs des facteurs de transcription et leurs utilisations |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| WO2015074081A1 (fr) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Compositions de benzopipérazine en tant qu'inhibiteurs de bromodomaines bet |
| PT3071203T (pt) * | 2013-11-18 | 2021-03-11 | Forma Therapeutics Inc | Composições de tetra-hidroquinolina como inibidores de bromodomínio bet |
| JP2017529358A (ja) | 2014-09-19 | 2017-10-05 | ジェネンテック， インコーポレイテッド | がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用 |
| WO2016086200A1 (fr) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300 |
| CA2973185C (fr) | 2015-01-08 | 2021-02-16 | Advinus Therapeutics Limited | Modulateurs/inhibiteurs bicycliques d'azote de tete de pont de gamma recepteur orphelin lie a l'acide retinoique (ror.gamma) |
| WO2016128908A1 (fr) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Composés bicycliques, compositions et applications médicinales correspondantes |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| WO2017205536A2 (fr) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Composés thérapeutiques et leurs utilisations |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2018195155A1 (fr) * | 2017-04-18 | 2018-10-25 | Celgene Quanticel Research, Inc. | Composés thérapeutiques |
| WO2019055877A1 (fr) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| KR20250067962A (ko) * | 2018-06-29 | 2025-05-15 | 포르마 세라퓨틱스 인크. | Creb 결합 단백질(cbp)의 저해 |
-
2019
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 CA CA3105099A patent/CA3105099A1/fr active Pending
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/fr not_active Ceased
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 IL IL313466A patent/IL313466B2/en unknown
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/fr active Pending
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MX342385B (es) | Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b. | |
| MA33730B1 (fr) | Procédés de synthèse pour des composés spiro-oxindoles | |
| MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MA32300B1 (fr) | Anticorps anti-facteur d humanises et utilisations de ceux-ci | |
| BRPI0416361A (pt) | métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente | |
| MA52219B1 (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA29976B1 (fr) | Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires. | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| ZA202210560B (en) | Inhibiting creb binding protein (cbp) | |
| EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
| BR0210721A (pt) | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA40378A (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine | |
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| MA30592B1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| MA31198B1 (fr) | Nouvelle forme dosifiee | |
| MA60154A1 (fr) | Inhibiteurs de line-1 pour traiter une maladie | |
| MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. |